The $350 break-even threshold
CVS’s analysis focused on patients newly taking the popular GLP-1 medicines from Eli Lilly and Novo Nordisk, which mimic the GLP-1 hormone and reduce appetite, and compared them with similar patients not taking the drugs. The medicines included Mounjaro and Ozempic for diabetes and Zepbound and Wegovy for obesity, with patients starting treatment between 2023 and 2025.
The key conclusion is that at current prices, GLP-1 drugs raise total spending because they are too expensive to be offset by lower medical costs. Only below $350 a month does the equation balance. The analysis did not break out figures for obesity patients alone.
When drug costs outweigh the savings
According to CVS, GLP-1 use was associated with 10% to 12% fewer emergency room visits in the first and second years. The company examined records for 60,000 people in the first year and 20,000 people in the second.

















